ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,665.60
-1.30%
S&P ASX All Technology
3,036.50
-0.65%
Brent Oil
84.66
0.40%
US Dollar vs AUD
1.5047
0.03%
Bitcoin
67,849.32
-0.65%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ARYA Sciences Acquisition Corporation IV (ARYD)

  7. ARYA Sciences Acquisition Corporation IV (ARYD) News

ARYD

ARYA Sciences Acquisitio... (ARYD)

ARYA Sciences Acquisition Corporation IV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARYD
DateTimeSourceHeadlineSymbolCompany
21/05/202411:31Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
21/05/202407:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
17/05/202406:41Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
17/05/202406:15Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
06/05/202420:25GlobeNewswire Inc.Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
29/02/202409:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
29/02/202409:02Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
27/02/202408:48Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
27/02/202408:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
16/02/202408:34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
16/02/202408:33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
15/02/202408:16Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
15/02/202408:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
15/02/202400:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
14/02/202422:29PR Newswire (US)Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
14/02/202422:06PR Newswire (US)Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation TechnologiesNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
10/02/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
03/02/202401:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
02/02/202409:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
31/01/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
23/01/202409:20Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
02/01/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
04/12/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
10/11/202308:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
03/11/202307:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
03/10/202308:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
28/09/202306:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
05/09/202320:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
12/08/202306:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARYDARYA Sciences Acquisition Corporation IV
03/08/202306:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARYDARYA Sciences Acquisition Corporation IV
 Showing the most relevant articles for your search:NASDAQ:ARYD

Your Recent History

LSE
IN96
Barclays 29
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved